Literature DB >> 11735341

Generation of species cross-reactive aptamers using "toggle" SELEX.

R White1, C Rusconi, E Scardino, A Wolberg, J Lawson, M Hoffman, B Sullenger.   

Abstract

Species cross-reactivity facilitates the preclinical evaluation of potentially therapeutic molecules in animal models. Here we describe an in vitro selection strategy in which RNA ligands (aptamers) that bind both human and porcine thrombin were selected by "toggling" the protein target between human and porcine thrombin during alternating rounds of selection. The "toggle" selection process yielded a family of aptamers, all of which bound both human and porcine thrombin with high affinity. Toggle-25, a characteristic member, inhibited two of thrombin's most important functions: plasma clot formation and platelet activation. If appropriate targets are available, the toggle strategy is a simple measure that promotes cross-reactivity and may be generalizable to related proteins of the same species as well as to other combinatorial library screening strategies. This strategy should facilitate the isolation of ligands with needed properties for gene therapy and other therapeutic and diagnostic applications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11735341     DOI: 10.1006/mthe.2001.0495

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  75 in total

1.  Selection strategy to generate aptamer pairs that bind to distinct sites on protein targets.

Authors:  Qiang Gong; Jinpeng Wang; Kareem M Ahmad; Andrew T Csordas; Jiehua Zhou; Jeff Nie; Ron Stewart; James A Thomson; John J Rossi; H Tom Soh
Journal:  Anal Chem       Date:  2012-06-08       Impact factor: 6.986

2.  Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.

Authors:  Erin E Soule; Kristin M Bompiani; Rebecca S Woodruff; Bruce A Sullenger
Journal:  Nucleic Acid Ther       Date:  2015-11-19       Impact factor: 5.486

Review 3.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

Review 4.  Modulation of the Coagulation Cascade Using Aptamers.

Authors:  Rebecca S Woodruff; Bruce A Sullenger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-08-27       Impact factor: 8.311

5.  Crystal structure of an RNA aptamer bound to thrombin.

Authors:  Stephen B Long; Meredith B Long; Rebekah R White; Bruce A Sullenger
Journal:  RNA       Date:  2008-10-29       Impact factor: 4.942

Review 6.  Designed and Evolved Nucleic Acid Nanotechnology: Contrast and Complementarity.

Authors:  Tulsi Ram Damase; Peter B Allen
Journal:  Bioconjug Chem       Date:  2019-01-03       Impact factor: 4.774

7.  Strategies for the discovery of therapeutic aptamers.

Authors:  Xianbin Yang; Na Li; David G Gorenstein
Journal:  Expert Opin Drug Discov       Date:  2011-01       Impact factor: 6.098

Review 8.  Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?

Authors:  S K Haßel; G Mayer
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

9.  In vitro isolation of class-specific oligonucleotide-based small-molecule receptors.

Authors:  Weijuan Yang; Haixiang Yu; Obtin Alkhamis; Yingzhu Liu; Juan Canoura; Fengfu Fu; Yi Xiao
Journal:  Nucleic Acids Res       Date:  2019-07-09       Impact factor: 16.971

10.  Origins of the enhanced affinity of RNA-protein interactions triggered by RNA phosphorodithioate backbone modification.

Authors:  Xianbin Yang; N Dinuka Abeydeera; Feng-Wu Liu; Martin Egli
Journal:  Chem Commun (Camb)       Date:  2017-09-21       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.